Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia.

MLA

Cavanna, L., et al. “Idarubicin plus Attenuated High-Dose Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Leukemia.” European Journal of Haematology, vol. 45, no. 3, Sept. 1990, pp. 180–81. EBSCOhost, https://doi.org/10.1111/j.1600-0609.1990.tb00450.x.

APA

Cavanna, L., Stasi, M., Fornari, F., Civardi, G., Sbolli, G., Moretto, M., & Buscarini, L. (1990). Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia. European Journal of Haematology, 45(3), 180–181. https://doi.org/10.1111/j.1600-0609.1990.tb00450.x

Chicago

Cavanna, L., M. Stasi, F. Fornari, G. Civardi, G. Sbolli, M. Moretto, and L. Buscarini. 1990. “Idarubicin plus Attenuated High-Dose Cytosine Arabinoside in the Treatment of Relapsed and Refractory Acute Leukemia.” European Journal of Haematology 45 (3): 180–81. doi:10.1111/j.1600-0609.1990.tb00450.x.